Monoklonal gammopati med ubestemt signifikans

Translated title of the contribution: Monoclonal gammopathy of undetermined significance

Niels Emil Ulrich Hermansen, Trine Silkjaer, Charlotte Toftmann Hansen, Thomas Granum Aagaard, Henrik Gregersen

Research output: Contribution to journalJournal articleResearchpeer-review


This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström’s macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.
Translated title of the contributionMonoclonal gammopathy of undetermined significance
Original languageDanish
Article numberV08190428
JournalUgeskrift for Laeger
Issue number20
Publication statusPublished - 2. Mar 2020


Dive into the research topics of 'Monoclonal gammopathy of undetermined significance'. Together they form a unique fingerprint.

Cite this